Back to search

National and Kapodistrian University of Athens

Σχεδιασμός, σύνθεση και φαρμακολογική αξιολόγηση νέων υποκατεστημένων ισοστερών πουρίνης

Abstract

dc:description

Purines are of great biological importance as they serve as structural components of the genetic material and of molecules involved in metabolic pathways and signaling mechanisms inside and outside the cell. For this reason, Purine analogs or isosters, compounds that mimic the normal Purine derivatives, can be used to treat a variety of diseases by targeting specific cellular processes associated with their pathogenesis. This approach has proven success, as shown by the various drugs of this class that have been approved in the recent decades. In the context of this effort, the object of the present PhD thesis is the Design, Synthesis and Pharmacological evaluation of novel substituted Purine isosters as potential anticancer agents.The content of this project is divided into three parts, which are described in detail in Chapters 1, 2 and 3. In the first part, using as lead compounds previously synthesized molecules in the laboratory which exhibited remarkable activity in various cancer cell lines, new substituted pyrazolo[3,4-c]pyridine derivatives, were designed, synthesized and then pharmacologically evaluated against A2058 melanoma as well as DU145 and PC3 prostate cancer cell lines, while selected compounds with high potency were further studied for their effect on the cell cycle.In the second part, new substituted Purine isosters, belonging to three different heterocyclic systems, were designed and synthesized as potential inhibitors of the Epidermal Growth Factor Receptor (EGFR). The lead compound was Lapatinib (Tykerb®), an approved drug that inhibits both EGFR and HER-2, another important member of this family of receptors. The new target molecules were evaluated as inhibitors of receptor phosphorylation at the cellular level, for their direct inhibitory action on the intracellular receptor kinase segment and for their cytotoxicity in the non-small cell lung cancer cell line A549 and breast cancer HCC1954, which are associated with overexpression of EGFR-WT and HER-2, respectively. The most potent derivatives were further studied for their cellular uptake levels and in vivo pharmacokinetic properties.The third part involves the design and synthesis of new pyrazolopyridines and pyrrolopyridines as potential inhibitors of the mutant B-RafV600E kinase, which occurs in about 50% of cases of melanoma. Vemurafenib (Zelboraf®), an approved drug that inhibits this specific enzyme and presents impressive therapeutic results, was used as the lead compound. The new target molecules belong to four different heterocyclic systems and during the writing of this thesis, their pharmacological evaluation was still underway.The last part summarizes the results of the three distinct projects and outlines the future objectives, which are, firstly, the exploitation of the structure-activity relationships extracted in each project, which combined with the in silico study of the target binding of the molecules, will guide the design of the next generation of derivatives, and secondly, the in vivo pharmacological evaluation of the compounds with the highest potency.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2018

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Gavriil, Efthymios-Spyridon
  • Γαβριήλ, Ευθύμιος-Σπυρίδων

Subjects

dc:subject × 12

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/43780

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Gavriil, Efthymios-Spyridon; Γαβριήλ, Ευθύμιος-Σπυρίδων. Σχεδιασμός, σύνθεση και φαρμακολογική αξιολόγηση νέων υποκατεστημένων ισοστερών πουρίνης. National and Kapodistrian University of Athens, 2018. http://hdl.handle.net/10442/hedi/43780